Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-05-24
DOI
10.3389/fendo.2019.00245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial
- (2019) S Delaloge et al. ANNALS OF ONCOLOGY
- Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
- (2018) N C Turner et al. ANNALS OF ONCOLOGY
- Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
- (2018) R J Hartmaier et al. ANNALS OF ONCOLOGY
- Targeting FGFR pathway in breast cancer
- (2018) J. Perez-Garcia et al. BREAST
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
- (2018) Rinath Jeselsohn et al. CANCER CELL
- Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
- (2018) MN Dickler et al. CANCER RESEARCH
- ER+Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
- (2018) Angel L. Guerrero-Zotano et al. CLINICAL CANCER RESEARCH
- U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
- (2018) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2−Advanced Breast Cancer
- (2018) Erika P. Hamilton et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
- (2018) Bettina Wingelhofer et al. LEUKEMIA
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- FDA approves first-in-class SYK inhibitor
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Linking inflammation and cancer: the unexpected SYK world
- (2018) Juan Fueyo et al. NEURO-ONCOLOGY
- Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer
- (2018) Alacoque L. Browne et al. ONCOGENE
- Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.
- (2018) Xiaoling Puyang et al. Cancer Discovery
- Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair
- (2018) Dominika Tempka et al. Redox Biology
- Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
- (2018) Navid Sobhani et al. Cells
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Abstract 3509: The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models
- (2018) Ethan D. Emberley et al. CANCER RESEARCH
- Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
- (2018) Hope S. Rugo et al. EUROPEAN JOURNAL OF CANCER
- SOX9/FXYD3/Src axis is critical for ER+ breast cancer stem cell function
- (2018) Yue Xue et al. MOLECULAR CANCER RESEARCH
- Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor
- (2018) Deli Hong et al. MOLECULAR CANCER RESEARCH
- The prognostic effects of somatic mutations in ER-positive breast cancer
- (2018) Obi L. Griffith et al. Nature Communications
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
- (2018) Jonathan T. Lei et al. Cell Reports
- Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
- (2018) E S Sokol et al. ANNALS OF ONCOLOGY
- G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen
- (2018) Tanja Ignatov et al. BREAST CANCER RESEARCH AND TREATMENT
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
- (2018) Greg P. Coffey et al. CLINICAL CANCER RESEARCH
- Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
- (2018) Sarah Croessmann et al. CLINICAL CANCER RESEARCH
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
- (2018) Utthara Nayar et al. NATURE GENETICS
- Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
- (2018) Mehmet Kahraman et al. ACS Medicinal Chemistry Letters
- The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
- (2017) Andrew M K Law et al. ENDOCRINE-RELATED CANCER
- GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer
- (2017) Luis Molina et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6
- (2017) Noritaka Yamaguchi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
- (2017) Andreas Heindl et al. JNCI-Journal of the National Cancer Institute
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells
- (2017) Joshua D. Stender et al. MOLECULAR CELL
- LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer
- (2017) Lu Lu et al. Molecular Medicine Reports
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
- (2017) Rinath Jeselsohn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
- (2017) Eneda Toska et al. SCIENCE
- Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
- (2017) Jennifer M. Giltnane et al. Science Translational Medicine
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Defective DNA repair mechanisms in prostate cancer: impact of olaparib
- (2017) Francesca De Felice et al. Drug Design Development and Therapy
- Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine
- (2017) Cheng Guo et al. Oncotarget
- Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer
- (2017) Nguyen Thi Thuy Phuong et al. Oncotarget
- MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer
- (2017) Giuseppina Roscigno et al. Oncotarget
- Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
- (2017) Andreas Heindl et al. JNCI-Journal of the National Cancer Institute
- Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes
- (2017) Ewelina Wiśnik et al. Scientific Reports
- Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
- (2017) Ana Sahores et al. CURRENT CANCER DRUG TARGETS
- Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype
- (2016) Xianghui Zou et al. ANTIOXIDANTS & REDOX SIGNALING
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr
- (2016) F Andre et al. CANCER RESEARCH
- AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
- (2016) H. M. Weir et al. CANCER RESEARCH
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
- (2016) Mai Tomiguchi et al. CANCER SCIENCE
- HES1 in immunity and cancer
- (2016) Aradhana Rani et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Membrane and nuclear estrogen receptor α collaborate to suppress adipogenesis but not triglyceride content
- (2016) Ali Pedram et al. FASEB JOURNAL
- The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients
- (2016) Lisa König et al. HUMAN IMMUNOLOGY
- Selective binding of estrogen receptor α to ubiquitin chains
- (2016) Valeria Pesiri et al. IUBMB LIFE
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
- (2016) Greg Coffey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- STAT5 in Cancer and Immunity
- (2016) Aradhana Rani et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy
- (2016) Zhen-Ru Liu et al. LIFE SCIENCES
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells
- (2016) S Bhatt et al. ONCOGENE
- FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
- (2016) Xiaoyong Fu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxic control of metastasis
- (2016) E. B. Rankin et al. SCIENCE
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
- (2016) Takashi Takeshita et al. Oncotarget
- Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
- (2016) Raie T. Bekele et al. Scientific Reports
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER
- (2015) Erin Zekas et al. BMC CANCER
- Genes targeted by the Hedgehog-signaling pathway can be regulated by Estrogen related receptor β
- (2015) Yuan Lu et al. BMC MOLECULAR BIOLOGY
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Adaptive Immune Regulation of Mammary Postnatal Organogenesis
- (2015) Vicki Plaks et al. DEVELOPMENTAL CELL
- Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion
- (2015) Gillian Browne et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling
- (2015) Javier A. Menendez et al. JNCI-Journal of the National Cancer Institute
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity
- (2015) R. C. D'Angelo et al. MOLECULAR CANCER THERAPEUTICS
- TNFα Signaling Exposes Latent Estrogen Receptor Binding Sites to Alter the Breast Cancer Cell Transcriptome
- (2015) Hector L. Franco et al. MOLECULAR CELL
- Progesterone receptor modulates ERα action in breast cancer
- (2015) Hisham Mohammed et al. NATURE
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer
- (2015) Jun Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast
- (2015) Xiaoqing Jia et al. Oncotarget
- MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ*
- (2015) Mingrong Lü et al. Scientific Reports
- Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling
- (2015) Javier A. Menendez et al. JNCI-Journal of the National Cancer Institute
- HIF-1α pathway: role, regulation and intervention for cancer therapy
- (2015) Georgina N. Masoud et al. Acta Pharmaceutica Sinica B
- Actionable pharmacogenetic markers for prediction and prognosis in breast cancer
- (2015) Keith Sacco et al. EPMA Journal
- An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling
- (2015) Hui Xu et al. PLoS One
- Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease
- (2015) Heidi N. Hilton et al. Oncotarget
- Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype
- (2015) Gyu-Beom Jang et al. Scientific Reports
- Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
- (2014) Yifang Wei et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
- (2014) RS Finn et al. CANCER RESEARCH
- GPER Mediates Activation of HIF1 /VEGF Signaling by Estrogens
- (2014) E. M. De Francesco et al. CANCER RESEARCH
- Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis
- (2014) Arnoud J. Templeton et al. CANCER TREATMENT REVIEWS
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer
- (2014) Aoife Ward et al. JOURNAL OF PATHOLOGY
- GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells
- (2014) Tenghua Yu et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
- (2014) J Cui et al. ONCOGENE
- Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes
- (2014) A R Daniel et al. ONCOGENE
- SYK Allelic Loss and the Role of Syk-Regulated Genes in Breast Cancer Survival
- (2014) Jan Blancato et al. PLoS One
- Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer
- (2014) Rui Huang et al. PLoS One
- Steroid receptor coactivators: servants and masters for control of systems metabolism
- (2014) Erin Stashi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Recurrent ESR1–CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
- (2014) Jamunarani Veeraraghavan et al. Nature Communications
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- GPER Mediates Estrogen-Induced Signaling and Proliferation in Human Breast Epithelial Cells and Normal and Malignant Breast
- (2014) Allison L. Scaling et al. Hormones & Cancer
- Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
- (2014) Theerawut Chanmee et al. Cancers
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
- (2013) Xiaoyong Fu et al. BREAST
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
- (2013) P. Fan et al. CANCER RESEARCH
- Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway
- (2013) BRUNA COROMINAS-FAJA et al. CELL CYCLE
- Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
- (2013) A. K. Dunbier et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
- (2013) Sherene Loi et al. JNCI-Journal of the National Cancer Institute
- STAT signaling in different breast cancer sub-types
- (2013) Priscilla A. Furth MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells
- (2013) Guangliang Li et al. Molecular Oncology
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Role of Glutathione in Cancer Progression and Chemoresistance
- (2013) Nicola Traverso et al. Oxidative Medicine and Cellular Longevity
- Tracking progesterone receptor-mediated actions in breast cancer
- (2013) Todd P. Knutson et al. PHARMACOLOGY & THERAPEUTICS
- CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis
- (2013) Danny W. K. Lum et al. PLoS One
- Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
- (2013) L. Magnani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells
- (2013) J Yun et al. Oncogenesis
- Breast cancer and other neoplasms in women with neurofibromatosis type 1: A retrospective review of cases in the Detroit metropolitan area
- (2012) X. Wang et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- NFκB signaling is important for growth of antiestrogen resistant breast cancer cells
- (2012) Christina W. Yde et al. BREAST CANCER RESEARCH AND TREATMENT
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
- (2012) D. H. Fagan et al. CANCER RESEARCH
- Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
- (2012) B. Ramaswamy et al. CANCER RESEARCH
- Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
- (2012) A.M. Gonzalez-Angulo et al. CANCER TREATMENT REVIEWS
- New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer
- (2012) Viviana Bartella et al. CELLULAR SIGNALLING
- AIB1:ER Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells
- (2012) J. O'Hara et al. CLINICAL CANCER RESEARCH
- Minireview: G Protein-Coupled Estrogen Receptor-1, GPER-1: Its Mechanism of Action and Role in Female Reproductive Cancer, Renal and Vascular Physiology
- (2012) Edward J. Filardo et al. ENDOCRINOLOGY
- Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver
- (2012) M. D. Wallace et al. GENETICS
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types
- (2012) Francisco Ferro de Beça et al. JOURNAL OF CLINICAL PATHOLOGY
- Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers
- (2012) Sarah C. Baumgarten et al. MOLECULAR ENDOCRINOLOGY
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells
- (2012) G Castoria et al. ONCOGENE
- Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
- (2012) A Ward et al. ONCOGENE
- LMTK3 is implicated in endocrine resistance via multiple signaling pathways
- (2012) J Stebbing et al. ONCOGENE
- Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic Signaling
- (2012) Kazufumi Ohshiro et al. PLoS One
- Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
- (2012) W. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deciphering the retinoblastoma protein phosphorylation code
- (2012) Seth M. Rubin TRENDS IN BIOCHEMICAL SCIENCES
- Reversing multidrug resistance by tyrosine kinase inhibitors
- (2012) Miao He et al. Chinese Journal of Cancer
- Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
- (2012) Emily M. Fox et al. Frontiers in Oncology
- G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer
- (2011) Atanas Ignatov et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
- (2011) E. M. Fox et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
- (2011) C. K. Osborne et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
- (2011) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
- (2011) Muriel Le Romancer et al. ENDOCRINE REVIEWS
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
- (2011) Diana M Cittelly et al. Molecular Cancer
- Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5
- (2011) Xiang-Ping Yang et al. NATURE IMMUNOLOGY
- Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer
- (2011) Georgios Giamas et al. NATURE MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
- (2011) A Bergamaschi et al. ONCOGENE
- Sox2 expression in breast tumours and activation in breast cancer stem cells
- (2011) O Leis et al. ONCOGENE
- Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer
- (2011) L. F. Hernandez-Aya et al. ONCOLOGIST
- Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development
- (2011) Masahito Kawazu et al. PLoS One
- Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
- (2011) A. M. Mendes-Pereira et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences
- (2011) Leonora Balaj et al. Nature Communications
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2.
- (2010) Christopher C Williams et al. BMC BIOCHEMISTRY
- Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
- (2010) Yanyuan Wu et al. BMC CANCER
- Significance of ER–Src axis in hormonal therapy resistance
- (2010) Sreeram Vallabhaneni et al. BREAST CANCER RESEARCH AND TREATMENT
- 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer
- (2010) H Sova et al. BRITISH JOURNAL OF CANCER
- Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically.
- (2010) Liam Morgan et al. CANCER BIOLOGY & THERAPY
- Interaction of Developmental Transcription Factor HOXC11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer
- (2010) M. McIlroy et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Estrogen Receptor- Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
- (2010) J. Bostner et al. CLINICAL CANCER RESEARCH
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
- (2010) A. F. Leary et al. CLINICAL CANCER RESEARCH
- Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) M. Cristofanilli et al. CLINICAL CANCER RESEARCH
- Centrosomal Localization of Cyclin E-Cdk2 Is Required for Initiation of DNA Synthesis
- (2010) Rebecca L. Ferguson et al. CURRENT BIOLOGY
- Clinical significance of estrogen receptor phosphorylation
- (2010) L. C. Murphy et al. ENDOCRINE-RELATED CANCER
- BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells
- (2010) Ruchi Nehra et al. FASEB JOURNAL
- CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
- (2010) Christophe Ginestier et al. JOURNAL OF CLINICAL INVESTIGATION
- MicroRNA-101-mediated Akt activation and estrogen-independent growth
- (2010) M Sachdeva et al. ONCOGENE
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) L. S. Schwartzberg et al. ONCOLOGIST
- ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
- (2010) Sheng-Li Lin et al. PLoS One
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
- (2010) Fiona M. Blows et al. PLOS MEDICINE
- Syk and pTyr'd: Signaling through the B cell antigen receptor
- (2009) Robert L. Geahlen BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells
- (2009) Atanas Ignatov et al. BREAST CANCER RESEARCH AND TREATMENT
- Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells
- (2009) M Murohashi et al. BRITISH JOURNAL OF CANCER
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
- (2009) Dimitrios Iliopoulos et al. CELL
- Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
- (2009) L. M. McGlynn et al. CLINICAL CANCER RESEARCH
- NF-κB and estrogen receptor α interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells
- (2009) Nathalie Gionet et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis
- (2009) S S Kwek et al. ONCOGENE
- Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer
- (2009) G Liu et al. ONCOGENE
- Targeting Src in breast cancer
- (2008) R. S. Finn ANNALS OF ONCOLOGY
- Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
- (2008) Elizabeth Iorns et al. CANCER CELL
- Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
- (2008) C. J. Creighton et al. CANCER RESEARCH
- Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
- (2008) P. Rizzo et al. CANCER RESEARCH
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
- (2008) C. Desmedt et al. CLINICAL CANCER RESEARCH
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
- (2008) Tyler E. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
- (2008) Jiang Fan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis
- (2008) Chad J. Creighton et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
- (2008) Daniele Generali et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity
- (2008) Ross S Thomas et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- (2008) LANCET ONCOLOGY
- Regulation of Estrogen Rapid Signaling through Arginine Methylation by PRMT1
- (2008) Muriel Le Romancer et al. MOLECULAR CELL
- Progesterone Receptor Rapid Signaling Mediates Serine 345 Phosphorylation and Tethering to Specificity Protein 1 Transcription Factors
- (2008) Emily J. Faivre et al. MOLECULAR ENDOCRINOLOGY
- Transient cyclical methylation of promoter DNA
- (2008) Sara Kangaspeska et al. NATURE
- MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways
- (2008) B CHESKIS et al. STEROIDS
- Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer
- (2007) Farhad Vesuna et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Epigenetic inactivation of microRNA genehsa-mir-9-1in human breast cancer
- (2007) U Lehmann et al. JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More